Webinar Antibody Discovery

Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies

November 15, 2023

Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is to target the pHLA complex mimicking TCR recognition. In this webinar, Dr. W. Frank […]

Read More

Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform

August 30, 2023

Speaker: Yanan Guo, Ph.D. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals GPCRs (G protein-coupled receptor) are the most abundant membrane protein in the human genome, and are targeted by approximately one-third of drugs on the market. However, the difficulty in antigen preparation and novel GPCR-targeting antibody screening has posed significant challenges […]

Read More

Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety

July 20, 2023

Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, in combination with the targeted delivery of cytotoxic payloads for potent tumor cell killing. […]

Read More

Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMab, RenLite & RenNano Mice

June 21, 2023

Speaker: Li Hui, MD, PhD. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston  Therapeutic development of antibodies and antibody-based drugs is a multi-year process that involves high cost and significant risk. In recent years, a common discovery approach to ensure the quality of new anti-human therapeutic antibodies is to express select human immunoglobulin genes in […]

Read More

Generation and discovery of high affinity antibodies

May 2, 2022

Speaker: Li Hui, MD, Ph.D. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Introduced Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat. Provided proof-of-concept data supporting the robust capabilities of the platform to identify high-quality antibodies with therapeutic potential.

Read More

Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice

March 18, 2022

Speaker: Yi (Benny) Yang, Ph.D.  Chief Scientific Officer, Biocytogen Beijing Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets Analyzed the design, screening and drug discovery of bispecific antibodies and bispecific-ADC drugs in two case studies

Read More

Back to top